{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["adjuvant treatment", "herbal medicine", "non-small cell lung cancer", "traditional Chinese medicine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36567455", "DateCompleted": {"Year": "2022", "Month": "12", "Day": "27"}, "DateRevised": {"Year": "2023", "Month": "10", "Day": "23"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["15347354221144312", "10.1177/15347354221144312"], "Journal": {"ISSN": "1552-695X", "JournalIssue": {"Volume": "21", "PubDate": {"Year": "2022", "Season": "Jan-Dec"}}, "Title": "Integrative cancer therapies", "ISOAbbreviation": "Integr Cancer Ther"}, "ArticleTitle": "Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future.", "Pagination": {"StartPage": "15347354221144312", "MedlinePgn": "15347354221144312"}, "Abstract": {"AbstractText": ["Lung carcinoma is the primary reason for cancer-associated mortality, and it exhibits the highest mortality and incidence in developed and developing countries. Non-small cell lung cancer (NSCLC) and SCLC are the 2 main types of lung cancer, with NSCLC contributing to 85% of all lung carcinoma cases. Conventional treatment mainly involves surgery, chemoradiotherapy, and immunotherapy, but has a dismal prognosis for many patients. Therefore, identifying an effective adjuvant therapy is urgent. Historically, traditional herbal medicine has been an essential part of complementary and alternative medicine, due to its numerous targets, few side effects and substantial therapeutic benefits. In China and other East Asian countries, traditional herbal medicine is increasingly popular, and is highly accepted by patients as a clinical adjuvant therapy. Numerous studies have reported that herbal extracts and prescription medications are effective at combating tumors. It emphasizes that, by mainly regulating the P13K/AKT signaling pathway, the Wnt signaling pathway, and the NF-\u03baB signaling pathway, herbal medicine induces apoptosis and inhibits the proliferation and migration of tumor cells. The present review discusses the anti-NSCLC mechanisms of herbal medicines and provides options for future adjuvant therapy in patients with NSCLC."]}, "AuthorList": [{"Identifier": ["0000-0003-2782-2453"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Huang", "ForeName": "Jie", "Initials": "J"}, {"Identifier": ["0000-0002-7489-8840"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Li", "ForeName": "Jia-Xin", "Initials": "JX"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Ma", "ForeName": "Lin-Rui", "Initials": "LR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Xu", "ForeName": "Dong-Han", "Initials": "DH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Wang", "ForeName": "Peng", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Li", "ForeName": "Li-Qi", "Initials": "LQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Yu", "ForeName": "Li-Li", "Initials": "LL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Li", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China."}], "LastName": "Li", "ForeName": "Run-Ze", "Initials": "RZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Zhang", "ForeName": "Hao", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Zheng", "ForeName": "Yu-Hong", "Initials": "YH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Southern Medical University, Guangzhou, Guangdong, China."}, {"Identifier": [], "Affiliation": "Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Guangzhou, Guangdong, China."}, {"Identifier": [], "Affiliation": "Guangdong Provincial Engineering Laboratory of Chinese Medicine Preparation Technology, Guangzhou, Guangdong, China."}], "LastName": "Tang", "ForeName": "Ling", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Macau University of Science and Technology, Taipa, Macau, China."}], "LastName": "Yan", "ForeName": "Pei-Yu", "Initials": "PY"}], "PublicationTypeList": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Integr Cancer Ther", "NlmUniqueID": "101128834", "ISSNLinking": "1534-7354"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pathology"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": ["metabolism"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Herbal Medicine"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Wnt Signaling Pathway"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Carcinoma"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}], "CoiStatement": "The author(s) declared no potential conflicts of interest with respect to the\nresearch, authorship, and/or publication of this article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.", "ArticleIdList": ["33538338"]}, {"Citation": "Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535-554.", "ArticleIdList": ["34273294"]}, {"Citation": "Dawkins JBN, Webster RM. The small-cell lung cancer drug market. Nat Rev Drug Discov. 2020;19:507-508.", "ArticleIdList": ["32235872"]}, {"Citation": "Gridelli C, Rossi A, Carbone DP, et al.. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.", "ArticleIdList": ["27188576"]}, {"Citation": "Ettinger DS, Wood DE, Aisner DL, et al.. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Ne. 2021;19:254-266.", "ArticleIdList": ["33668021"]}, {"Citation": "Lachgar A, Tazi MA, Afif M, Er-Raki A, Kebdani T, Benjaafar N. Lung cancer: incidence and survival in Rabat, Morocco. Morocco Rev Epidemiol Sante. 2016;64:391-395.", "ArticleIdList": ["27793413"]}, {"Citation": "Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446-454.", "ArticleIdList": ["29364287"]}, {"Citation": "Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345-1356.", "ArticleIdList": ["34385702"]}, {"Citation": "Jiao L, Dong C, Liu J, et al.. Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep. 2017;7:46524.", "ArticleIdList": ["PMC5402288", "28436479"]}, {"Citation": "Maemondo M, Inoue A, Kobayashi K, et al.. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388.", "ArticleIdList": ["20573926"]}, {"Citation": "Lim SM, Kim HR, Lee JS, et al.. Open-label, Multicenter, PHASE II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35:2613-2618.", "ArticleIdList": ["28520527"]}, {"Citation": "Planchard D, Mazieres J, Riely GJ, et al.. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation\u2013positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2013;31:8009-8009."}, {"Citation": "Soria JC, Ohe Y, Vansteenkiste J, et al.. Osimertinib in untreatedEGFR-mutated advanced non\u2013small-Cell lung cancer. N Engl J Med. 2018;378:113-125.", "ArticleIdList": ["29151359"]}, {"Citation": "Drilon A, Siena S, Dziadziuszko R, et al.. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:261-270.", "ArticleIdList": ["PMC7811790", "31838015"]}, {"Citation": "Garon EB, Rizvi NA, Hui R, et al.. Pembrolizumab for the treatment of non\u2013small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.", "ArticleIdList": ["25891174"]}, {"Citation": "Spigel D, de Marinis F, Giaccone G, et al.. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1\u2013selected NSCLC. Ann Oncol. 2019;30:v915."}, {"Citation": "Antonia SJ, Gettinger SN, Chow LQM, et al.. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol. 2014;32:8023-8023."}, {"Citation": "Borghaei H, Langer CJ, Gadgeel S, et al.. 24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non\u2013small cell lung cancer. J Thorac Oncol. 2019;14:124-129.", "ArticleIdList": ["30138764"]}, {"Citation": "Theelen WSME, Peulen HMU, Lalezari F, et al.. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276-1282.", "ArticleIdList": ["PMC6624814", "31294749"]}, {"Citation": "Hirsch FR, Scagliotti GV, Mulshine JL, et al.. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299-311.", "ArticleIdList": ["27574741"]}, {"Citation": "An X, Zhang Y, Duan L, et al.. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. Biomed Pharmacother. 2021;137:111267.", "ArticleIdList": ["PMC7836975", "33508618"]}, {"Citation": "Merarchi M, Dudha N, Das BC, Garg M. Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs. Phytother Res. 2021;35:5384-5396.", "ArticleIdList": ["PMC8441929", "34132421"]}, {"Citation": "Li SG, Chen HY, Ou-Yang CS, et al.. The efficacy of Chinese herbal medicine as an adjunctive therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e57604.", "ArticleIdList": ["PMC3585199", "23469033"]}, {"Citation": "Xu B, Zhang H, Wang Y, Huang S, Xu L. Mechanism of Xu Li's experiential prescription for the treatment of EGFR-positive NSCLC. Evid-Based Compl Alt. 2020;2020:8787153.", "ArticleIdList": ["PMC7091530", "32256661"]}, {"Citation": "Louren\u00e7o AM, Ferreira LM, Branco PS. Molecules of natural origin, semi-synthesis and synthesis with anti-inflammatory and anticancer utilities. Curr Pharm Des. 2012;18:3979-4046.", "ArticleIdList": ["22632756"]}, {"Citation": "Orlikova B, Legrand N, Panning J, Dicato M, Diederich M. Anti-inflammatory and anticancer drugs from nature. Cancer Treat Res. 2014;159:123-143.", "ArticleIdList": ["24114478"]}, {"Citation": "Xu W, Yang G, Xu Y, et al.. The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid-Based Compl Alt. 2014;2014:278917.", "ArticleIdList": ["PMC4137694", "25165478"]}, {"Citation": "Lee HY, Meng M, Liu Y, Su T, Kwan HY. Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer. Oncol Lett. 2021;22:646.", "ArticleIdList": ["PMC8299012", "34386068"]}, {"Citation": "Lu Y, Sun C, Jiao L, Liu Y, Gong Y, Xu L. Chinese herbal medicine combined with first-generation EGFR-TKIs in treatment of advanced non-small cell lung cancer with EGFR sensitizing mutation: a systematic review and meta-analysis.. Front Pharmacol. 2021;12:698371.", "ArticleIdList": ["PMC8429791", "34512332"]}, {"Citation": "Jin H, Park SB, Yoon JH, Lee JY, Kim EH, Yoon SW. Traditional herbal medicine combined with first-line platinum-based chemotherapy for advanced non-small-cell lung cancer: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2021;100:e27163.", "ArticleIdList": ["PMC8448030", "34664842"]}, {"Citation": "Horie S. Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol. 2012;53:665-672.", "ArticleIdList": ["PMC3490085", "23136625"]}, {"Citation": "Sarkar FH, Li Y, Wang Z, Padhye S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr Pharm Des. 2010;16:1801-1812.", "ArticleIdList": ["PMC3093025", "20345353"]}, {"Citation": "Rinc\u00f3n-P\u00e9rez J, Rodr\u00edguez-Hern\u00e1ndez L, Ru\u00edz-Valdiviezo VM, et al.. Fatty acids profile, phenolic compounds and antioxidant capacity in elicited callus of Thevetia peruviana (Pers.) K. Schum. J Oleo Sci. 2016;65:311-318.", "ArticleIdList": ["26972464"]}, {"Citation": "Yao C, Su L, Zhang F, et al.. Thevebioside, the active ingredient of traditional Chinese medicine, promotes ubiquitin-mediated SRC-3 degradation to induce NSCLC cells apoptosis. Cancer Lett. 2020;493:167-177.", "ArticleIdList": ["32829007"]}, {"Citation": "Jin J, Wang T, Wang Y, et al.. SRC3 expressed in BMSCs promotes growth and migration of multiple myeloma cells by regulating the expression of Cx43. Int J Oncol. 2017;51:1694-1704.", "ArticleIdList": ["PMC5673026", "29075794"]}, {"Citation": "Dasgupta S, Rajapakshe K, Zhu B, et al.. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018;556:249-254.", "ArticleIdList": ["PMC5895503", "29615789"]}, {"Citation": "Thuy TD, Phan NN, Wang CY, et al.. Novel therapeutic effects of sesamin on diabetes-induced cardiac dysfunction. Mol Med Rep. 2017;15:2949-2956.", "ArticleIdList": ["PMC5428537", "28358428"]}, {"Citation": "Noguchi T, Ikeda K, Sasaki Y, Yamamoto J, Yamori Y. Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2004;31 Suppl 2:S24-S26.", "ArticleIdList": ["15649279"]}, {"Citation": "Akl M, Ayoub N, Sylvester P. Mechanisms mediating the synergistic anticancer effects of combined \u03b3-Tocotrienol and sesamin treatment. Planta Med. 2012;78:1731-1739.", "ArticleIdList": ["22987298"]}, {"Citation": "Deng P, Wang C, Chen L, et al.. Sesamin induces cell cycle arrest and apoptosis through the inhibition of signal transducer and activator of transcription 3 signalling in human hepatocellular carcinoma cell line HepG2. Biol Pharm Bull. 2013;36:1540-1548.", "ArticleIdList": ["24088253"]}, {"Citation": "Harikumar KB, Sung B, Tharakan ST, et al.. Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products. Mol Cancer Res. 2010;8:751-761.", "ArticleIdList": ["PMC2895997", "20460401"]}, {"Citation": "Chen Y, Li H, Zhang W, et al.. Corrigendum to \u201cSesamin suppresses NSCLC cell proliferation through cyclin D1 inhibition-dependent cell cycle arrest via Akt/p53 pathway\u201d [Toxicology and applied pharmacology, 387 (2020) 114848]. Toxicol Appl Pharmacol. 2020;400:115048.", "ArticleIdList": ["32428595"]}, {"Citation": "Fang Q, Zhu Y, Wang Q, Song M, Gao G, Zhou Z. Suppression of cyclooxygenase 2 increases chemosensitivity to sesamin through the Akt-PI3K signaling pathway in lung cancer cells. Int J Mol Med. 2019;43:507-516.", "ArticleIdList": ["30365050"]}, {"Citation": "Yang S, Li X, Dou H, Hu Y, Che C, Xu D. Sesamin induces A549 cell mitophagy and mitochondrial apoptosis via a reactive oxygen species-mediated reduction in mitochondrial membrane potential. Korean J Physiol Pharmacol. 2020;24:223-232.", "ArticleIdList": ["PMC7193912", "32392913"]}, {"Citation": "Lei W, Huo Z. Jervine inhibits non-small cell lung cancer (NSCLC) progression by suppressing Hedgehog and AKT signaling via triggering autophagy-regulated apoptosis. Biochem Biophys Res Commun. 2020;533:397-403.", "ArticleIdList": ["32972750"]}, {"Citation": "Pan S-T, Zhou J, Yang F, Zhou S-F, Ren T. Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells. BMC Cancer. 2020;20:634.", "ArticleIdList": ["PMC7346405", "32641008"]}, {"Citation": "Wei X, Liu W, Wang JQ, Tang Z. \u201cHedgehog pathway\u201d: a potential target of itraconazole in the treatment of cancer. J Cancer Res Clin. 2020;146:297-304.", "ArticleIdList": ["31960187"]}, {"Citation": "Klein SD, Nguyen DC, Bhakta V, et al.. Mutations in the sonic hedgehog pathway cause macrocephaly-associated conditions due to crosstalk to the PI3K/AKT/mTOR pathway. Am J Med Genet A. 2019;179:2517-2531.", "ArticleIdList": ["PMC7346528", "31639285"]}, {"Citation": "Nagoor Meeran MF, Javed H, Al Taee H, Azimullah S, Ojha SK. Pharmacological properties and molecular mechanisms of thymol: prospects for its therapeutic potential and pharmaceutical development. Front Pharmacol. 2017;8:380.", "ArticleIdList": ["PMC5483461", "28694777"]}, {"Citation": "Li C, Thompson MA, Tamayo AT, et al.. Over-expression of thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget. 2012;3:314-326.", "ArticleIdList": ["PMC3359887", "22447839"]}, {"Citation": "Dashtaki A, Mahjoub S, Zabihi E, Pourbagher R. The effects of pre-treatment and post-treatment of thymol against tert-butyl hydroperoxide (t-BHP) cytotoxicity in MCF-7 cell line and fibroblast derived foreskin. Rep Biochem Mol Biol. 2020;9:338-347.", "ArticleIdList": ["PMC7816789", "33649728"]}, {"Citation": "De La Chapa JJ, Singha PK, Lee DR, Gonzales CB. Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis. J Oral Pathol Med. 2018;47:674-682.", "ArticleIdList": ["PMC6105452", "29777637"]}, {"Citation": "Balan DJ, Rajavel T, Das M, Sathya S, Jeyakumar M, Devi KP. Thymol induces mitochondrial pathway-mediated apoptosis via ROS generation, macromolecular damage and SOD diminution in A549 cells. Pharmacol Rep. 2021;73:240-254.", "ArticleIdList": ["33095436"]}, {"Citation": "Elbe H, Yigitturk G, Cavusoglu T, Uyanikgil Y, Ozturk F. Apoptotic effects of thymol, a novel monoterpene phenol, on different types of cancer. Bratisl Med J. 2021;121:122-128.", "ArticleIdList": ["32115964"]}, {"Citation": "Koparal AT, Zeytinoglu M. Effects of carvacrol on a human non-small cell lung cancer (NSCLC) cell line, A549. Cytotechnology. 2003;43:149-154.", "ArticleIdList": ["PMC3449592", "19003220"]}, {"Citation": "Mancuso C, Santangelo R. Panax ginseng and Panax quinquefolius: from pharmacology to toxicology. Food Chem Toxicol. 2017;107:362-372.", "ArticleIdList": ["PMC7116968", "28698154"]}, {"Citation": "Unlu A, Nayir E, Kirca O, Ay H, Ozdogan M. Ginseng and cancer. J Buon. 2016;21:1383-1387.", "ArticleIdList": ["28039696"]}, {"Citation": "Majeed F, Malik FZ, Ahmed Z, Afreen A, Afzal MN, Khalid N. Ginseng phytochemicals as therapeutics in oncology: recent perspectives. Biomed Pharmacother. 2018;100:52-63.", "ArticleIdList": ["29421582"]}, {"Citation": "Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS. A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy. Zhonghua Zhong Liu Za Zhi. 2018;40:295-299.", "ArticleIdList": ["29730918"]}, {"Citation": "Zhang YH, Li HD, Li B, Jiang SD, Jiang LS. Ginsenoside Rg3 induces DNA damage in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells. Oncol Rep. 2014;31:919-925.", "ArticleIdList": ["24337872"]}, {"Citation": "Poon PY, Kwok HH, Yue PYK, et al.. Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage. Drug Metab Dispos. 2012;40:120-129.", "ArticleIdList": ["21956953"]}, {"Citation": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.", "ArticleIdList": ["30620402"]}, {"Citation": "Bhattacharjee S, Nandi S. Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer. Clin Transl Med. 2016;5:45-52. doi:10.1186/s40169-016-0128-z", "ArticleIdList": ["10.1186/s40169-016-0128-z", "PMC5136664", "27921283"]}, {"Citation": "Liu T, Zuo L, Guo D, et al.. Ginsenoside Rg3 regulates DNA damage in non-small cell lung cancer cells by activating VRK1/P53BP1 pathway. Biomed Pharmacother. 2019;120:109483.", "ArticleIdList": ["31629252"]}, {"Citation": "Campillo-Marcos I, Lazo PA. Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target? Cell Mol Life Sci. 2018;75:2375-2388.", "ArticleIdList": ["PMC5986855", "29679095"]}, {"Citation": "Sanz-Garc\u00eda M, Monsalve DM, Sevilla A, Lazo PA. Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage. J Biol Chem. 2012;287:23757-23768.", "ArticleIdList": ["PMC3390650", "22621922"]}, {"Citation": "Tan Q, Lin S, Zeng Y, et al.. Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells. Environ Toxicol. 2020;35:643-651.", "ArticleIdList": ["31916386"]}, {"Citation": "Jiang Z, Yang Y, Yang Y, et al.. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. Biomed Pharmacother. 2017;96:378-383.", "ArticleIdList": ["29031195"]}, {"Citation": "Wang XJ, Zhou RJ, Zhang N, Jing Z. 20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy. Eur J Pharmacol. 2019;850:141-149.", "ArticleIdList": ["30772396"]}, {"Citation": "Gruenwald J, Freder J, Armbruester N. Cinnamon and health. Crit Rev Food Sci Nutr. 2010;50:822-834.", "ArticleIdList": ["20924865"]}, {"Citation": "Long M, Tao S, Rojo de la Vega M, et al.. Nrf2-dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. Cancer Prev Res. 2015;8:444-454.", "ArticleIdList": ["PMC4417412", "25712056"]}, {"Citation": "Chang WL, Cheng FC, Wang SP, Chou ST, Shih Y. Cinnamomum cassiaessential oil and its major constituent cinnamaldehyde induced cell cycle arrest and apoptosis in human oral squamous cell carcinoma HSC-3 cells. Environ Toxicol. 2017;32:456-468.", "ArticleIdList": ["26919256"]}, {"Citation": "Wu C, Zhuang Y, Jiang S, et al.. Cinnamaldehyde induces apoptosis and reverses epithelial-mesenchymal transition through inhibition of Wnt/\u03b2-catenin pathway in non-small cell lung cancer. Int J Biochem Cell Biol. 2017;84:58-74.", "ArticleIdList": ["28093328"]}, {"Citation": "Tian F, Yu CT, Ye WD, Wang Q. Cinnamaldehyde induces cell apoptosis mediated by a novel circular RNA hsa_circ_0043256 in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;493:1260-1266.", "ArticleIdList": ["28958934"]}, {"Citation": "Hong SH, Ismail IA, Kang SM, Han DC, Kwon BM. Cinnamaldehydes in Cancer Chemotherapy. Phytother Res. 2016;30:754-767.", "ArticleIdList": ["26890810"]}, {"Citation": "Park J, Baek SH. Combination therapy with cinnamaldehyde and hyperthermia induces apoptosis of A549 Non-Small cell lung carcinoma cells via regulation of reactive oxygen species and mitogen-activated protein kinase family. Int J Mol Sci. 2020;21:6229.", "ArticleIdList": ["PMC7504317", "32872198"]}, {"Citation": "Boldbaatar A, Lee S, Han S, et al.. Eupatolide inhibits the TGF-\u03b21-induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5. Oncol Lett. 2017;14:6031-6039.", "ArticleIdList": ["PMC5661662", "29113242"]}, {"Citation": "Adekenov SM. Sesquiterpene lactones with unusual structure. Their biogenesis and biological activity. Fitoterapia. 2017;121:16-30.", "ArticleIdList": ["28579552"]}, {"Citation": "Lee J, Hwangbo C, Lee JJ, Seo J, Lee JH. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol Rep. 2010;23:229-237.", "ArticleIdList": ["19956887"]}, {"Citation": "Ma X, Wu K, Xu A, Jiao P, Li H, Xing L. The sesquiterpene lactone eupatolide induces apoptosis in non-small cell lung cancer cells by suppressing STAT3 signaling. Environ Toxicol Pharmacol. 2021;81:103513.", "ArticleIdList": ["33091599"]}, {"Citation": "Banerjee K, Resat H. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Cancer. 2016;138:2570-2578.", "ArticleIdList": ["PMC4801660", "26559373"]}, {"Citation": "Bezerra DP, Pessoa C, Moraes MOD, et al.. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J Appl Toxicol. 2008;28:599-607.", "ArticleIdList": ["17975786"]}, {"Citation": "Golovine K, Makhov P, Teper E, et al.. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate. 2012;73:23-30.", "ArticleIdList": ["PMC3491117", "22592999"]}, {"Citation": "Raj L, Ide T, Gurkar AU, et al.. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475:231-234.", "ArticleIdList": ["PMC3316487", "21753854"]}, {"Citation": "Zheng J, Son DJ, Gu SM, et al.. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway. Sci Rep. 2016;6:26357.", "ArticleIdList": ["PMC4873819", "27198178"]}, {"Citation": "Gagat M, Ha\u0142as-Wi\u015bniewska M, Zieli\u0144ska W, Izdebska M, Grzanka D, Grzanka A. The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1. Onco Targets Ther. 2018;11:8275-8292.", "ArticleIdList": ["PMC6255113", "30538497"]}, {"Citation": "Lewis KM, Bharadwaj U, Eckols TK, et al.. Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer. Lung Cancer. 2015;90:182-190.", "ArticleIdList": ["PMC4619129", "26410177"]}, {"Citation": "Zhang Y, Zhao Y, Wu Y, et al.. Ophiopogon saponin C1 inhibits lung tumors by stabilizing endothelium permeability via inhibition of PKC\u03b4. Int J Biol Sci. 2020;16:396-407.", "ArticleIdList": ["PMC6990896", "32015677"]}, {"Citation": "Fouzder C, Mukhuty A, Kundu R. Kaempferol inhibits Nrf2 signalling pathway via downregulation of Nrf2 mRNA and induces apoptosis in NSCLC cells. Arch Biochem Biophys. 2021;697:108700.", "ArticleIdList": ["33271149"]}, {"Citation": "Nakamura K, Shinozuka K, Yoshikawa N. Anticancer and antimetastatic effects of cordycepin, an active component of Cordyceps sinensis. J Pharmacol Sci. 2015;127:53-56.", "ArticleIdList": ["25704018"]}, {"Citation": "Zhou Y, Zhan Z, Tang Y, Duan J., Zhang X. Mechanisms of proliferative inhibition by maimendong & qianjinweijing decoction in A549 cells. Zhongguo Fei Ai Za Zhi. 2010;13:477-482.", "ArticleIdList": ["PMC6000691", "20677645"]}, {"Citation": "Fan Y, Ma Z, Zhao L, et al.. Anti-tumor activities and mechanisms of traditional Chinese medicines formulas: a review. Biomed Pharmacother. 2020;132:110820.", "ArticleIdList": ["33035836"]}, {"Citation": "Jiang Z, Ma Y, Tian T, et al.. Maimendong and Qianjinweijing Tang (Jin formula) suppresses lung cancer by regulation of miR-149-3p. J Ethnopharmacol. 2020;258:112836.", "ArticleIdList": ["32344160"]}, {"Citation": "Xiong F, Jiang M, Chen M, et al.. Study on inhibitory effect of MaiMenDong decoction and WeiJing decoction combination with cisplatin on NCI-A549 xenograft in nude mice and its mechanism. J Cancer. 2017;8:2449-2455.", "ArticleIdList": ["PMC5595074", "28900482"]}, {"Citation": "Xia K, Zeng Y, Hao W, et al.. Clinic study of Maimendong Tang combining with EP regimen in treatment for patients with advanced non-small cell lung cancer. J Liaoning Univ Tradit Chin Med. 2015;42:1705-1707."}, {"Citation": "Lu J, Chen J, Kang Y, et al.. Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells. Oncol Lett. 2018;16:4343-4352.", "ArticleIdList": ["PMC6126349", "30197670"]}, {"Citation": "Han M-Q. Effects of Yifei Kangliu Qral Liquid on cell cycle and protein-nucleic acid synthesis of experimental lung cancer. Zhong Xi Yi Jie He Xue Bao. 2003;1:205-208. Chinese.", "ArticleIdList": ["15339563"]}, {"Citation": "Liu J, Pan M, Li Y, Ye D, Guo Y, Li Y. Clinical study of oral liquid Jin Fu Kang for the treatment of primary non-small cell lung cancer. Tumor (Shanghai). 2001;21:463-465."}, {"Citation": "Jiao L, Wang Y, Xu L, You M. Lung cancer prevention and therapy using the JinFuKang herbal mixture. Curr Pharmacol Rep. 2015;1:346-353."}, {"Citation": "Huang X, Sun J, Sun J. Combined treatment with JFKD and gefitinib overcomes drug resistance in non-small cell lung cancer. Curr Pharm Biotechnol. 2021;22:389-399.", "ArticleIdList": ["32819223"]}, {"Citation": "Chang YY, Tsai YT, Lai JN, Yeh CH, Lin SK. The traditional Chinese medicine prescription patterns for migraine patients in Taiwan: a population-based study. J Ethnopharmacol. 2014;151:1209-1217.", "ArticleIdList": ["24389028"]}, {"Citation": "Zhu K, Fukasawa I, Furuno M, et al.. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol. 2005;97:405-409.", "ArticleIdList": ["15863137"]}, {"Citation": "Gou H, Gu L, Shang B, Xiong Y, Wang C. Protective effect of Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, on 5-fluorouracil-induced intestinal mucositis in mice. Hum Exp Toxicol. 2016;35:1243-1251.", "ArticleIdList": ["26801985"]}, {"Citation": "Xiong Y, Shang B, Xu S, Zhao R, Gou H, Wang C. Protective effect of Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, on 5-fluorouracil-induced renal injury in mice. Ren Fail. 2016;38:1240-1248.", "ArticleIdList": ["27435211"]}, {"Citation": "Yu N, Xiong Y, Wang C. Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, enhances cisplatin cytotoxicity in A549/DDP cells through induction of apoptosis and autophagy. Biomed Res Int. 2017;2017:3692797.", "ArticleIdList": ["PMC5244006", "28154825"]}, {"Citation": "Ouyang M, Liu Y, Tan W, et al.. Bu-Zhong-Yi-Qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model. BMC Complement Altern Med. 2014;14:497.", "ArticleIdList": ["PMC4300826", "25511260"]}, {"Citation": "Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Japanese herbal medicine in patients with advanced lung cancer: prolongation of survival? J Altern Complement Med. 2002;8:107-108.", "ArticleIdList": ["12006117"]}, {"Citation": "Tatsumi K, Shinozuka N, Nakayama K, Sekiya N, Kuriyama T, Fukuchi Y. Hochuekkito improves systemic inflammation and nutritional status in elderly patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2009;57:169-170.", "ArticleIdList": ["19170793"]}, {"Citation": "Ji XM, Wu ZC, Liu GW, et al.. Wenxia Changfu Formula (\u6e29\u4e0b\u80a0\u8151\u65b9) induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice. Chin J Integr Med. 2016;22:752-758.", "ArticleIdList": ["26666762"]}, {"Citation": "Zhang Y, Wu Z, Yu H, et al.. Chinese herbal medicine Wenxia Changfu Formula reverses cell adhesion-mediated drug resistance via the integrin \u03b21-PI3K-AKT pathway in lung cancer.. J Cancer. 2019;10:293-304.", "ArticleIdList": ["PMC6360309", "30719123"]}, {"Citation": "Ji XM, Ouyang B, Liu H, et al.. In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer. Chin J Integr Med. 2011;17:908-916.", "ArticleIdList": ["22139542"]}, {"Citation": "Wang MR, Chen RJ, Zhao F, et al.. Effect of Wenxia Changfu formula combined with cisplatin reversing non-small cell lung cancer cell adhesion-mediated drug resistance. Front Pharmacol. 2020;11:500137.", "ArticleIdList": ["PMC7527591", "33041787"]}, {"Citation": "Wang Q, Acharya N, Liu Z, et al.. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells. J Ethnopharmacol. 2018;217:140-151.", "ArticleIdList": ["29458146"]}, {"Citation": "Liu Z. Overcoming the drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancer cell lines. 2018."}, {"Citation": "Pang L, Han S, Jiao Y, et al.. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. Int J Oncol. 2017;51:25-38.", "ArticleIdList": ["PMC5467788", "28534943"]}, {"Citation": "He XR, Han SY, Li XH, et al.. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor \u03b21 signaling pathway in vitro and in vivo. J Ethnopharmacol. 2017;204:45-57.", "ArticleIdList": ["28412214"]}, {"Citation": "Zhao X, Dai X, Wang S, et al.. Traditional Chinese medicine integrated with chemotherapy for stage II-IIIA patients with non-small-cell lung cancer after radical surgery: a retrospective clinical analysis with small sample size. Evid-Based Compl Alt. 2018;2018:1-7.", "ArticleIdList": ["PMC6083736", "30147731"]}, {"Citation": "McCulloch M, See C, Shu XJ, et al.. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24:419-430.", "ArticleIdList": ["16421421"]}, {"Citation": "Nagasaka A, Kawane K, Yoshida H, Nagata S. Apaf-1-independent programmed cell death in mouse development. Cell Death Differ. 2010;17:931-941.", "ArticleIdList": ["19960021"]}, {"Citation": "Burgess DJ. Apoptosis: refined and lethal. Nat Rev Cancer. 2013;13:79.", "ArticleIdList": ["23344537"]}, {"Citation": "Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395-417.", "ArticleIdList": ["PMC8211386", "32203277"]}, {"Citation": "Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature. 2010;466:68-76.", "ArticleIdList": ["PMC2901998", "20562859"]}, {"Citation": "Hu Y, Li X, Lin L, Liang S, Yan J. Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis. Oncol Rep. 2018;39:1731-1738.", "ArticleIdList": ["29393465"]}, {"Citation": "Ganesh K, Massagu\u00e9 J. Targeting metastatic cancer. Nat Med. 2021;27:34-44.", "ArticleIdList": ["PMC7895475", "33442008"]}, {"Citation": "Yang J, He D, Peng Y, et al.. Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition. Onco Targets Ther. 2017;10:5209-5217.", "ArticleIdList": ["PMC5667780", "29138573"]}, {"Citation": "Hashimoto O, Shinkawa M, Torimura T, et al.. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.. BMC Cancer. 2006;6:292.", "ArticleIdList": ["PMC1770931", "17177986"]}, {"Citation": "Liu C-M, Shen H-T, Lin Y-A, et al.. Antiproliferative and antimetastatic effects of praeruptorin C on human non-small cell lung cancer through inactivating ERK/CTSD signalling pathways. Molecules. 2020;25:1625.", "ArticleIdList": ["PMC7180937", "32244796"]}, {"Citation": "Zheng B, Wang G, Gao W, Wu Q, Zhu W, Weng G. SOX7 is involved in polyphyllin D-induced G0/G1 cell cycle arrest through down-regulation of cyclin D1. Acta Pharm. 2020;70:191-200.", "ArticleIdList": ["31955140"]}, {"Citation": "Hayano T, Garg M, Yin D, et al.. SOX7 is down-regulated in lung cancer. J Exp Clin Cancer Res. 2013;32:17.", "ArticleIdList": ["PMC3648366", "23557216"]}, {"Citation": "Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46:372-383.", "ArticleIdList": ["24897931"]}, {"Citation": "Poma P, Labbozzetta M, D\u2019Alessandro N, Notarbartolo M. NF-\u03baB is a potential molecular drug target in triple-negative breast cancers. OMICS. 2017;21:225-231.", "ArticleIdList": ["28388298"]}, {"Citation": "Zhao B, Hui X, Jiao L, et al.. A TCM formula YYWY inhibits tumor growth in non-small cell lung cancer and enhances immune-response through facilitating the maturation of dendritic cells. Front Pharmacol. 2020;11:798.", "ArticleIdList": ["PMC7301756", "32595493"]}, {"Citation": "Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 2015;5:17663.", "ArticleIdList": ["PMC4668392", "26631279"]}, {"Citation": "Garg M, Shanmugam MK, Bhardwaj V, et al.. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Med Res Rev. 2021;41:1291-1336.", "ArticleIdList": ["33289118"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "26", "Hour": "0", "Minute": "13"}, {"Year": "2022", "Month": "12", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "12", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "12", "Day": "25"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36567455", "PMC9806388", "10.1177/15347354221144312"]}}], "PubmedBookArticle": []}